Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy

Elisabetta Walters, Mark F Cotton, Helena Rabie, H Simon Schaaf, Lourens O Walters, Ben J Marais, Elisabetta Walters, Mark F Cotton, Helena Rabie, H Simon Schaaf, Lourens O Walters, Ben J Marais

Abstract

Background: The tuberculosis (TB) and human immunodeficiency virus (HIV) epidemics are poorly controlled in sub-Saharan Africa, where highly active antiretroviral treatment (HAART) has become more freely available. Little is known about the clinical presentation and outcome of TB in HIV-infected children on HAART.

Methods: We performed a comprehensive file review of all children who commenced HAART at Tygerberg Children's Hospital from January 2003 through December 2005.

Results: Data from 290 children were analyzed; 137 TB episodes were recorded in 136 children; 116 episodes occurred before and 21 after HAART initiation; 10 episodes were probably related to immune reconstitution inflammatory syndrome (IRIS). The number of TB cases per 100 patient years were 53.3 during the 9 months prior to HAART initiation, and 6.4 during post HAART follow-up [odds ratio (OR) 16.6; 95% confidence interval (CI) 12.5-22.4]. A positive outcome was achieved in 97/137 (71%) episodes, 6 (4%) cases experienced no improvement, 16 (12%) died and the outcome could not be established in 18 (13%). Mortality was less in children on HAART (1/21; 4.8%) compared to those not on HAART (15/116; 12.9%).

Conclusion: We recorded an extremely high incidence of TB among HIV-infected children, especially prior to HAART initiation. Starting HAART at an earlier stage is likely to reduce morbidity and mortality related to TB, particularly in TB-endemic areas. Management frequently deviated from standard guidelines, but outcomes in general were good.

Figures

Figure 1
Figure 1
Schematic overview of the study population.

References

    1. (Revised March 2006, accessed 10 April 2007)
    1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis. Global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009–1021. doi: 10.1001/archinte.163.9.1009.
    1. Marais BJ, Hesseling AC, Gie RP, Schaaf HS, Beyers N. The burden of childhood tuberculosis and the accuracy of routine surveillance data in a high burden setting. Int J Tuberc Lung Dis. 2006;10:259–263.
    1. Nelson LJ, Wells CD. Tuberculosis in children: considerations for children from developing countries. Semin Pediatr Infect Dis. 2004;15:150–154. doi: 10.1053/j.spid.2004.05.007.
    1. Soeters M, de Vries AM, Kimpen JLL, Donald PR, Schaaf HS. Clinical features and outcome in children admitted to a TB hospital in the Western Cape – the influence of HIV infection and drug resistance. SAMJ. 2005;95:602–606.
    1. Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, Kasolo F, Mwaba P, Bhat G, Terunuma H, Zumla A. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet. 2002;360:985–990. doi: 10.1016/S0140-6736(02)11082-8.
    1. Jeena PM, Pillay P, Pillay T, Coovadia HM. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis. 2002;6:672–678.
    1. Kiwanuka J, Graham SM, Coulter JBS, Gondwe JS, Chilewani N, Carty H, Hart CA. Diagnosis of pulmonary tuberculosis in children in an HIV-endemic area, Malawi. Annals of Tropical Paediatrics. 2001;21:5–14.
    1. Mukadi YD, Wiktor S, Coulibaly I, Coulibaly D, Mbengue A, Folquet AM, Ackah A, Sassan-Morokro M, Bonnard D, Maurice C, Nolan C, Kreiss JK, Greenberg AE. Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Cote d'Ivoire. AIDS. 1997;11:1151–1158. doi: 10.1097/00002030-199709000-00011.
    1. Chan SP, Birnbaum J, Rao M, Steiner P. Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J. 1996;15:443–447. doi: 10.1097/00006454-199605000-00012.
    1. Jeena PM, Mitha T, Bamber S, Wesley A, Coutsoudis A, Coovadia HM. Effects of the human immunodeficiency virus on tuberculosis in children. Tubercle and Lung Dis. 1996;77:437–443. doi: 10.1016/S0962-8479(96)90117-3.
    1. Swaminathan S. Tuberculosis in HIV-infected children. Paediatric Respiratory Reviews. 2004;5:225–230. doi: 10.1016/j.prrv.2004.04.006.
    1. Schaaf HS, Krook S, Hollemans DW, Warren RM, Donald PR, Hesseling AC. Recurrent Culture-Confirmed Tuberculosis in Human Immunodeficiency Virus-Infected Children. Pediatr Infect Dis J. 2005;24:685–691. doi: 10.1097/01.inf.0000172933.22481.36.
    1. Schaaf HS, Geldenhuys A, Gie RP, Cotton MF. Culture-positive tuberculosis in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J. 1998;17:599–604. doi: 10.1097/00006454-199807000-00005.
    1. Espinal MA, Reingold AL, Pérez G, Camilo E, Soto S, Cruz E, Matos N, Gonzalez G. Human immunodeficiency virus infection in children with tuberculosis in Santo Domingo, Dominican Republic: prevalence, clinical findings, and response to antituberculosis treatment. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:155–159.
    1. Lawn SD, Wood R. Tuberculosis control in South Africa – will HAART help? SAMJ. 2006;96:502–504.
    1. Bonnet M, Pinoges L, Varaine F, Oberhauser BBO, O'Brien DDO, Kebede YYK, Hewison CCH, Zachariah RRZ, Ferradini LLF. Tuberculosis after HAART initiation in HIV- positive patients from five countries with a high tuberculosis burden. AIDS. 2006;20:1275–1279. doi: 10.1097/.
    1. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605–1612.
    1. Corbett EL, Marston B, Churchyard GJ, De Kock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet. 2006;367:926–937. doi: 10.1016/S0140-6736(06)68383-9.
    1. Doerholt K, Duong T, Tookey P, Butler K, Lyall H, Sharland M, Novelli V, Riordan A, Dunn D, Walker AS, Gibb DM, the collaborative HIVPaediatric Study (CHIPS) Outcomes for human immunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J. 2006;25:420–426. doi: 10.1097/01.inf.0000214994.44346.d3.
    1. Verweel G, van Rossum AM, Hartwig NG, Wolfs TFW, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type-1-infected children is associated with sustained effect on growth. Pediatrics. 2002;109:E25. doi: 10.1542/peds.109.2.e25.
    1. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infec Dis. 2002;2:93–102. doi: 10.1016/S1473-3099(02)00183-4.
    1. de Martino M, Toro PA, Balducci M, Galli L, Gabiano C, Rezza G, Pezzotti P. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV infection in children and the Italian National AIDS Registry. JAMA. 2000;284:190–197. doi: 10.1001/jama.284.2.190.
    1. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059–2064. doi: 10.1016/S0140-6736(02)08904-3.
    1. Girardi E, Palmieri F, Cingolani A, Ammassari A, Petrosillo N, Gillini L, Zinzi D, De Luca A, Antinori A, Ippolito G. Changing Clinical Presentation and Survival in HIV-Associated Tuberculosis after Highly Active Antiretroviral Therapy. JAIDS. 2001;26:326–331.
    1. Hung C, Chen MY, Hsiao CF, Hsieh S, Sheng W, Chang S. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS. 2003;17:2615–2622. doi: 10.1097/00002030-200312050-00008.
    1. Makombe SD, Harries AD, Yu JKL, Hochgesang M, Mhango E, Weigel R, Pasulani O, Fitzgerald M, Schouten EJ, Libamba E. Outcomes of tuberculosis patients who start antiretroviral therapy under routine programme conditions in Malawi. Int J Tuberc Lung Dis. 2007;11:412–416.
    1. Martinson N, Moultrieh H, Barry G, Violari A, Cotton M, Van Niekerk R, Kalete L, Coovadia A, Meyers T, Gray G. Incidence of tuberculosis in HIV-infected children: The influence of HAART. 13th CROI, Denver. 2006. p. Abstract 22.
    1. Kampmann B, Tena-Coki G, Nicol MP, Levin M, Eley B. Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART. AIDS. 2006;20:1011–1018. doi: 10.1097/01.aids.0000222073.45372.ce.
    1. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J. 2006;25:53–58. doi: 10.1097/01.inf.0000195618.55453.9a.
    1. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis. 2007;11:417–423.
    1. World Health Organisation Antiretroviral therapy in HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public health approach. WHO. 2006. (Accessed 7 May 2007)
    1. Burman WJ, Jones BE. Treatment of HIV-related Tuberculosis in the Era of Effective Antiretroviral Therapy. Am J Respir Crit Care Med. 2001;164:7–12.
    1. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis. 2007;11:417–423.
    1. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, Rabie H, Lombard CJ. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomized controlled trial. Brit Med J. 2006;334:136. doi: 10.1136/bmj.39000.486400.55.
    1. Marais BJ, Graham SM, Cotton M, Beyers N. Diagnosis and management challenges of childhood TB in the era of HIV. J Infect Dis. 2007;196:S76–S85. doi: 10.1086/518659.
    1. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Lombard C, Enarson DA, Beyers N. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics. 2006:e1350–1359. doi: 10.1542/peds.2006-0519.
    1. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Enarson DA, Beyers N. The spectrum of childhood tuberculosis in a highly endemic area. Int J Tuberc Lung Dis. 2006;10:732–738.
    1. The South African Department of Health Tuberculosis & HIV and AIDS Clinical Guidelines, launched October 2000 (Accessed 13 May 2007)
    1. World Health Organisation Guidelines for national tuberculosis programmes on the management of tuberculosis in children. WHO. 2006. (Accessed 12 May 2007)
    1. Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, Gie RP, Cotton MF, van Helden PD, Warren RM, Beyers N. Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis. 2005;42:548–558. doi: 10.1086/499953.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅